Home | Welcome to Contract Pharma   
Last Updated Monday, November 24 2014
Print

Breaking News

Related Searches:
December 29, 2010
Rhucin application at FDA  Read More »
December 29, 2010
CEO search commences  Read More »
December 22, 2010
Merrion Pharmaceuticals and Novo Nordisk have signed a collaboration and option agreement to evaluate the ability of Merrion's GIPET technology to boost the oral bioavailability of an undisclosed compound.  Read More »
December 22, 2010
GlaxoSmithKline and Theravance have initiated a Phase IIb study to evaluate the efficacy and safety of GSK961081 (‘081), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).  Read More »
December 22, 2010
Ligand Pharmaceuticals and Pfizer have sublicensed Tanaproget, also known as NSP-989, to a multi-national pharmaceutical company.  Read More »
December 22, 2010
Corcept Therapeutics Inc. achieved positive results from its Phase III study of Corlux for the treatment of Cushing's Syndrome.  Read More »
December 21, 2010
Pfizer plans to recall about 19,000 bottles of Lipitor in the U.S. due to reports of an uncharacteristic odor related to the bottles, which were supplied by a third-party manufacturer.  Read More »
December 21, 2010
Eli Lilly and Co. has completed the acquisition of Avid Radiopharmaceuticals, Inc. for an upfront payment of $300 million.   Read More »
December 21, 2010
Seth V. Hetherington, M.D., senior vice president of Clinical and Regulatory Affairs at Icagen, Inc., will be leaving the company at the end of the year.  Read More »
December 21, 2010
Emisphere Technologies, Inc. and Novo Nordisk have entered into an exclusive development and license agreement to develop and commercialize oral formulations of Novo Nordisk's insulins using Emisphere's Eligen Technology.  Read More »
December 20, 2010
Avila Therapeutics, Inc. has signed a worldwide strategic alliance with Sanofi-Aventis to discover targeted covalent drugs for the treatment of cancers.   Read More »
December 20, 2010
Bristol-Myers Squibb and Oncolys BioPharma, a privately-held biotechnology company based in Japan, have signed a definitive agreement under which BMS will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir.  Read More »
December 20, 2010
Gilead Sciences has signed an agreement to acquire Arresto Biosciences for $225 million and potential payments based on certain sales levels.  Read More »
December 20, 2010
Onyx Scientific has secured a contract with drug development company Nuformix to become one of its exclusive supply partners for characterization support.   Read More »
December 17, 2010
Commercial manufacturing revenues were flat at $144.8 million in the quarter.  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On